CD38‐EVs‐DoxMNs have superior efficacy and safety in treating plasmacytoma mice, compared to CD38‐EVs‐Doxi.v, providing novel insights into the potential of MNs as a platform for delivering targeted engineered EVs in tumour therapy. This evidence concerns the gene CD38 and plasmacytoma.